Navigation Links
Regeneron Submits Biologics License Application to FDA for VEGF Trap-Eye for Treatment of Wet Age-Related Macular Degeneration
Date:2/22/2011

TARRYTOWN, N.Y., Feb. 22, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that the company submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for VEGF Trap-Eye for the treatment of the neovascular form of age-related macular degeneration (wet AMD).  Under the Prescription Drug User Fee Act (PDUFA), the goal for a standard review time from submission to FDA action is ten months.  Regeneron's submission includes a request for Priority Review, which, if granted, would shorten the FDA's targeted goal for review time under PDUFA to six months.

"There have been significant advances in the treatment of wet AMD in recent years.  However, the need for monthly intravitreal injections to obtain optimal vision gains has resulted in a significant burden for physicians, patients, and their caregivers," said Leonard S. Schleifer, M.D., Ph.D., President and Chief Executive Officer of Regeneron.  "We are extremely proud to have conducted the largest global Phase 3 clinical program in patients with wet AMD, which demonstrated that patients treated with VEGF Trap-Eye 2 mg every two months, following three loading doses, were able to be dosed with fewer injections over one year without compromising efficacy.  We look forward to working closely with the FDA to bring this potentially important new medicine to patients with wet AMD."  

The VEGF Trap-Eye BLA is based on the positive results from two Phase 3 trials, the North American VIEW 1 trial and the global VIEW 2 trial.  In these trials, all regimens of VEGF Trap-Eye, including VEGF Trap-Eye dosed 2 milligrams (mg) every two months (following three loading doses), successfully met the primary endpoint of non-inferiority, compared to the current standard of care, ranibizumab 0.5 mg dosed every month.  The primary endpoi
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
2. Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
3. Enrollment Completed in Regeneron and Bayer HealthCare Phase 3 Studies of VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration (Wet AMD)
4. Regeneron Announces Presentation at the 18th Annual Credit Suisse Healthcare Conference
5. Regeneron Reports Third Quarter 2009 Financial and Operating Results
6. Sanofi-aventis and Regeneron Expand Strategic Antibody Collaboration
7. Regeneron Announces Presentation at the Deutsche Bank 2009 Biotech Boston Confab
8. BioMed Realty Trust Signs New Lease With Regeneron Pharmaceuticals for 131,000 Square Feet at Landmark
9. Regeneron Announces Presentation at the Morgan Stanley Global Healthcare Conference
10. Regeneron Announces Presentation at the UBS Global Life Sciences Conference
11. Regeneron Announces Panel Discussion at Citis 5th Annual Biotech Day
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... -- Kindred Hospital Houston Northwest, with Wound Care Specialists, ... new outpatient wound healing center.  The wound healing ... hard to heal wounds. Chronic wounds include diabetic ... leg wounds related to blood flow issues, post-surgical ... wounds which are complex and demonstrate delayed healing. ...
(Date:7/11/2014)... , July 11, 2014 Research and ... of the "Immunoprotein Diagnostic Testing Market - ... highest CAGR of 6% and is expected to ... to their offering. ... diagnostic testing has been segmented according to immunoprotein ...
(Date:7/10/2014)... MUMBAI, India , July 11, 2014 /PRNewswire/ ... the treatment of cancer are being highlighted in ... Mumbai from 10-12 July, 2014.  Renowned ... meeting to share best practices and exchange knowledge ... more precise, accurate and efficient. ...
Breaking Medicine Technology:Kindred Hospital Houston Northwest, With Wound Care Specialists, Opens Outpatient Wound Healing And Hyperbaric Center 2Immunoprotein Diagnostic Testing Market - Forecasts to 2019: Expected to grow at the highest CAGR of 6% and is expected to be valued at USD 4,943.0 million 2Improving quality and access to advanced cancer care in India and South Asia 2Improving quality and access to advanced cancer care in India and South Asia 3Improving quality and access to advanced cancer care in India and South Asia 4Improving quality and access to advanced cancer care in India and South Asia 5
... /PRNewswire-iReach/ -- Global Information, Inc. presents " ... Market Forecasts to 2018 "  by GlobalData. ... (PCOS) is a common chronic disorder of the endocrine ... age (12-45 years old) and is thought to be ...
... a privately held medical device company focused on developing ... Market, announced today that it has received CE Mark ... System in Europe. "This is a major ... are on Long Term Oxygen Therapy," said John Rush, ...
Cached Medicine Technology:GiiResearch.com: Polycystic Ovarian Syndrome (PCOS) Therapeutics - Market to Witness Static Growth Until 2018 2GiiResearch.com: Polycystic Ovarian Syndrome (PCOS) Therapeutics - Market to Witness Static Growth Until 2018 3Inova Labs Receives CE Mark Approval for the LifeChoice® Portable Oxygen Concentrator System 2
(Date:7/12/2014)... (PRWEB) July 12, 2014 With prom ... dress manufacturer and retailer, is ready to showcase its ... its new collection of evening dresses in its online ... to 67% off) for these elegant gowns. According to ... an end on July 26, 2014. , He ...
(Date:7/12/2014)... (PRWEB) July 12, 2014 Wright & Schulte ... DePuy Orthopedics , Inc., a subsidiary of Johnson & Johnson, ... suffers chronic pain after receiving a metal-on-metal DePuy Pinnacle hip ... to remove the artificial hip implant. The DePuy hip lawsuit ... Northern District of Texas (Case No. 3:14-cv-2427) where DePuy ...
(Date:7/12/2014)... 2014 Doylestown Hospital recently conducted an ... men’s health questions. Paddock tackles topics including main ... women live longer than men, and testosterone replacement therapy, ... Simple featured on Doylestown Hospital’s website, Dr. Brad ... any age. If you notice pain, bulging, or asymmetry ...
(Date:7/12/2014)... Utah (PRWEB) July 12, 2014 Utah ... types of startups, with awards being bestowed to companies ... spotlighted Utah’s outstanding entrepreneur community with recognition for new ... sustainable model with incoming revenue. , 25 Under 5 ... the state that are under 5 years old. Award ...
(Date:7/12/2014)... A recent article released by Seattle's well ... suggestions for those seeking cosmetic surgical procedures in summer ... and the heat begins to enliven the rainy Pacific Northwest, ... realizing that they didn’t work out as much during the ... a sudden surge of people eager to look their best ...
Breaking Medicine News(10 mins):Health News:VogueQueen.com Updates Its Summer Collection With New And Trendy Evening Dresses 2Health News:DePuy Pinnacle Hip Lawsuit Filed By Wright & Schulte LLC On Behalf of Ohio Man Who Required Revision Surgery Purportedly From Defective Hip Implant 2Health News:DePuy Pinnacle Hip Lawsuit Filed By Wright & Schulte LLC On Behalf of Ohio Man Who Required Revision Surgery Purportedly From Defective Hip Implant 3Health News:DePuy Pinnacle Hip Lawsuit Filed By Wright & Schulte LLC On Behalf of Ohio Man Who Required Revision Surgery Purportedly From Defective Hip Implant 4Health News:DePuy Pinnacle Hip Lawsuit Filed By Wright & Schulte LLC On Behalf of Ohio Man Who Required Revision Surgery Purportedly From Defective Hip Implant 5Health News:Ivyland Medical Center’s Dr. Brad Paddock Offers Tips for Men’s Health 2Health News:SquareHook is Recognized for UVEF 25 Businesses Under 5 Years-Watch Out 2Health News:Best Summer Cosmetic Surgeries Revealed in Article By Seattle Plastic Surgeon 2
... , , YSA and ... , , WASHINGTON, Aug. 10 ... the second year to offer UnitedHealth HEROES grants to youth-led ... Educators, service-learning coordinators, and students in the health professions are ...
... Long-standing liver disease has long been recognized to result ... various international studies, the overall incidence has varied from ... However, the reason for this is poorly understood. With ... and offering complete cure and long-term survival, bone disease ...
... age than is normal, researchers note , MONDAY, Aug. 10 ... the attacks on the Twin Towers on 9/11 may be ... blood. , Notably, half of the cases identified among law ... is usually a disease of the elderly. , "This ...
... , , , , ... now participate in the advanced stuttering treatment program at Hollins Communications ... at a substantially reduced cost through 2009 thanks to new stuttering ... , HCRI,s scholarship program is designed to broaden accessibility ...
... RONKONKOMA, N.Y., Aug. 10 NBTY, Inc. (NYSE: ... marketer of nutritional supplements, today announced that it will web cast the ... the Canaccord Adams Global Growth Conference in Boston on Thursday, ... to be web cast live on the Company Web site, ...
... , ROCHESTER, N.Y., Aug. 10 Your sleeping problems ... as Fibromyalgia (FM), and Chronic Fatigue Syndrome (CFS). But it can ... , , Recent studies show that ... review written by Professor Mark Opp from the University of Michigan ...
Cached Medicine News:Health News:Youth Find Innovative Solutions to Leading Health Threat 2Health News:Youth Find Innovative Solutions to Leading Health Threat 3Health News:Youth Find Innovative Solutions to Leading Health Threat 4Health News:9/11 Responders May Be At Raised Myeloma Risk 2Health News:9/11 Responders May Be At Raised Myeloma Risk 3Health News:Hollins Communications Research Institute Announces More Stuttering Therapy Scholarships 2Health News:NBTY to Web Cast Presentation at Canaccord Adams Global Growth Conference; Announces Preliminary Unaudited Net Sales Results for July 2009 2Health News:NBTY to Web Cast Presentation at Canaccord Adams Global Growth Conference; Announces Preliminary Unaudited Net Sales Results for July 2009 3Health News:Surprise! Better Sleep with Gene-Eden(R), an Antiviral Supplement 2Health News:Surprise! Better Sleep with Gene-Eden(R), an Antiviral Supplement 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: